Nasdaq nmra.

15 Sep 2023 ... ... Nasdaq under the NMRA ticker, which could give it a market valuation of $2.74 billion if fully exercised. It is also due to make its debut ...Nov 22, 2023 · Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways. Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November: Guggenheim Healthcare Talks 5th Annual INI …Neumora Therapeutics, Inc. (NASDAQ: NMRA) is a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Neumora is redefining neuroscience research and development with a data-driven precision neuroscience platform to cut through brain disease heterogeneity ...Shares of Neumora Therapeutics Inc (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange. RBC Capital Markets On Neumora Therapeutics.

Neumora Therapeutics (NASDAQ: NMRA) is owned by 23.77% institutional shareholders, 65.44% Neumora Therapeutics insiders, and 10.79% retail investors. Amgen Inc is the largest individual Neumora Therapeutics shareholder, owning 35.37M shares representing 23.16% of the company. Amgen Inc's Neumora Therapeutics shares are currently valued …Oct 14, 2023 · Neumora Therapeutics Inc. (NASDAQ: NMRA) grossed $250.1 million in a September initial public offering that was due in part to a drug pipeline that includes an experimental schizophrenia drug that ... Nov 22, 2023 · Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways. Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR).

View Our Latest Research Report on NMRA. Neumora Therapeutics Price Performance. NASDAQ:NMRA opened at $12.25 on Thursday. The stock has a fifty day simple moving average of $11.42.Complete Neumora Therapeutics Inc. stock information by Barron's. View real-time NMRA stock price and news, along with industry-best analysis.

Nov 27, 2023 · NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ... A Quick Take On Neumora Therapeutics. Neumora Therapeutics, Inc. ( NASDAQ: NMRA) has filed proposed terms to raise $250 million from the sale of its common stock in an IPO, according to an amended ...Oct 10, 2023 · In addition, NMRA-266 (M4R PAM), another drug in development for the treatment of schizophrenia, is viewed as a de-risked asset due to the large market and low entry barriers for this disease. Nov 23, 2023 · Neumora Therapeutics Inc. (NASDAQ:NMRA)’s traded shares stood at 0.14 million during the last session. At the close of trading, the stock’s price was $11.91, to imply an increase of 1.88% or $0.22 in intraday trading. The NMRA share’s 52-week high remains $17.74, putting it -48.95% down since ...

See the latest Neumora Therapeutics Inc stock price (NMRA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

NMRA Most Active Options. Most Active LEAPS Data is currently not available. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ...

The stock is expected to list on the Nasdaq under the ticker symbol “NMRA.” J.P. Morgan, BofA Securities, Guggenheim Securities, RBC Capital Markets and William Blair are the underwriters. The ...Andrey Tolkachev/iStock via Getty Images. Neumora Therapeutics ( NASDAQ: NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer ...For Neumora Therapeutics Inc (NASDAQ:NMRA), William Blair initiated coverage, by setting the current rating at Outperform. The stock has a 52-week-high of $17.74 and a 52-week-low of $9.90.27 Sep 2023 ... See the latest Neumora Therapeutics Inc stock price (NASDAQ:NMRA), related news, valuation, dividends and more to help you make your ...Dec 2, 2023 · Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) – Investment analysts at William Blair decreased their FY2023 earnings estimates for Neumora Therapeutics in a report issued on Monday, November 27th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($4.25) per share for the year, down from their previous estimate of […]

NASDAQ:NMRA; Company Type For Profit. Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain ...NMRA-266 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype, a clinically validated target for the treatment of schizophrenia. Neumora exclusively licensed ...Stock analysis for Neumora Therapeutics Inc (NMRA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.NVDA. NVIDIA Corporation Common Stock. $439.00 -16.81 -3.69%. Find the latest historical data for Nemaura Medical, Inc. Common Stock (NMRD) at Nasdaq.com. Nov 22, 2023 · Navacaprant is an investigational once-daily oral medication that is designed to modulate the dopamine and reward processing pathways. Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). CGC. Canopy Growth Corporation Common Shares. $1.275 -0.065 -4.85%. Find the latest SEC Filings data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com. Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last issued its earnings results on Wednesday, November 1st. The company reported ($1.14) earnings per share for the quarter, missing the ...

The latest Neumora Therapeutics stock prices, stock quotes, news, and NMRA history to help you invest and trade smarter. ... (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company ...Nov 30, 2023 · Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares rose 33.4% to $0.2326 in pre-market trading after falling 8% on Wednesday. Robert Davidow reported a14.5 % passive stake in Avenue Therapeutics in a ...

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last issued its earnings results on Wednesday, November 1st. The company reported ($1.14) earnings per share for the quarter, missing the ...Neumora Therapeutics Inc (NMRA). NASDAQ. Create Alert. Create Alert. New! Create Alert. Website. As an alert notification; To use this feature, make sure you ...Neumora Therapeutics, Inc. Common Stock (NMRA) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.Christoph Burgstedt/iStock via Getty Images. Company logo. I started a long position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) last week with a 4.2% portfolio allocation.This recent central ...14 Sep 2023 ... Home · News; NMRA. Neumora Therapeutics Inc. - NMRA STOCK NEWS. IMPACT. SENTIMENT. 11/27/2023 07:00 AM. NMRA : Nasdaq.NMRA-266 is an investigational positive allosteric modulator of the M4 muscarinic receptor subtype, a clinically validated target for the treatment of schizophrenia. Neumora exclusively licensed ...

Neumora Therapeutics, Inc. (NASDAQ: NMRA) is a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Neumora is redefining neuroscience research and development with a data-driven precision neuroscience platform to cut through brain disease heterogeneity ...

Nov 20, 2023 · Neumora Therapeutics is a biotech company located in Massachusetts, United States, which is part of the Healthcare sector, and is traded under the ticker NMRA on the NASDAQ exchange. Neumora Therapeutics stock last closed at $11.69 , down 1.35% from the previous day, and has decreased N/A in one year.

Nov 24, 2023 · Posted by Defense World Staff on Nov 24th, 2023. Shares of Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed ... --Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Robert Lenz, M.D., Ph.D., as executive vice ...4 hari yang lalu ... Moleculin Biotech (NASDAQ:MBRX) stock is jumping more than 15% without any clear news today. Neumora Therapeutics (NASDAQ:NMRA) shares are up ...Veja o histórico completo das cotações para Neumora Therapeutics Inc, consulte informações sobre o preço de fechamento, de abertura, máximas, mínimas e as …Sep 29, 2023 · Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ... $8.11 +0.06 +0.75% Find the latest Financials data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com. The latest price target for Neumora Therapeutics (NASDAQ: NMRA) was reported by JP Morgan on Wednesday, November 8, 2023. The analyst firm set a price target ...How much institutional buying is happening at Neumora Therapeutics? Institutional investors have bought a total of 11,743,056 shares in the last 24 months. This purchase volume represents approximately $165.69M in transactions. This page (NASDAQ:NMRA) was last updated on 11/28/2023 by MarketBeat.com Staff.

NASDAQ:NMRA Neumora Therapeutics (NMRA) Stock Price, News & Analysis $11.91 +0.22 (+1.88%) (As of 11/22/2023 ET) Compare Today's Range $11.76 $12.14 50-Day Range $9.64 $16.25 52-Week Range $9.35 $17.74 Volume 137,979 shs Average Volume 342,316 shs Market Capitalization $1.82 billion P/E Ratio N/A Dividend Yield N/A Price Target $22.67WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Instagram:https://instagram. saudi arabian oil companyxa100 enginemortgage lender washingtonbarrons baseball The stock’s previous close on October 9, 2023, was $12.14, but it opened higher on October 10, 2023, at $12.62. Throughout the trading day, NMRA stock experienced a range of prices, with the lowest price recorded at $11.25 and the highest price reached at $13.13. The trading volume on October 10, 2023, was significantly higher than …Sep 12, 2023 · A Quick Take On Neumora Therapeutics. Neumora Therapeutics, Inc. ( NASDAQ: NMRA) has filed proposed terms to raise $250 million from the sale of its common stock in an IPO, according to an amended ... 6 month treasury bill rate todaybest financial advisors philadelphia Andrey Tolkachev/iStock via Getty Images. Neumora Therapeutics (NASDAQ:NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO.Shares of the psychiatric drug developer opened ... healthcare reit etf Kymera Therapeutics Inc (NASDAQ:KYMR)’s traded shares stood at 0.36 million during the last session, with the company’s beta value hitting 2.03. At the close of trading, the stock’s price was $19.74, to imply an increase of 4.11% or $0.78 in intraday trading. The KYMR share’s 52-week high ...Nov 20, 2023 · Neumora Therapeutics is a biotech company located in Massachusetts, United States, which is part of the Healthcare sector, and is traded under the ticker NMRA on the NASDAQ exchange. Neumora Therapeutics stock last closed at $11.69 , down 1.35% from the previous day, and has decreased N/A in one year. Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.